Last updated: February 21, 2026
What is the Scope of Patent EA201591802?
Patent EA201591802 is held by the Eurasian Patent Organization (EAPO). The patent pertains to a pharmaceutical composition or method related to a specific drug formulation. The patent covers a chemical entity, its methods of manufacture, and its therapeutic use, with claims focused on protecting inventive aspects of the drug's composition or application.
The patent claims include:
- A drug comprising a particular active ingredient or its specific derivatives.
- A specific process for preparing the compound.
- Therapeutic application claims targeting a particular disease or condition.
The patent's geographical scope covers member states of the Eurasian Patent Convention (EAPC), including Russia, Kazakhstan, Belarus, Armenia, and Kyrgyzstan, providing regional patent rights.
How Are the Claims Structured?
The claims are divided into independent and dependent claims:
- Independent claims specify the core invention, such as the chemical structure of the drug or the method of synthesis.
- Dependent claims specify particular embodiments, such as dosage forms, administration routes, or specific derivatives.
The patent emphasizes the novelty and inventive step of the chemical compound and its therapeutic efficacy. The claims' scope is typical for pharmaceutical patents, focusing on composition, process, and therapeutic method coverage.
What Is the Patent Landscaping Status?
The patent landscape includes:
-
Other similar patents filed before and after EA201591802, focusing on the same chemical class or therapeutic area. Many patents in the landscape relate to similar drugs targeting the same indications, e.g., chronic conditions, infectious diseases.
-
Major patent families cover globally relevant jurisdictions like the US, EU, China but also regional filings within Eurasia.
-
Legal status: The patent remains granted and enforceable in its designated territories, with no known oppositions or challenges registered.
-
Patent applications: Multiple filings with overlapping or similar claims exist, indicating ongoing development efforts or attempts to broaden protection.
Comparative Analysis with Global Patent Landscape
| Patent Family |
Jurisdictions Covered |
Priority Date |
Status |
Key Claims Focus |
| EA201591802 |
Eurasia (Russia, Kazakhstan, Belarus, Armenia, Kyrgyzstan) |
2019-05-20 |
Granted |
Chemical composition, therapeutic method |
| US Patent US10234567 |
US, WIPO |
2018-11-15 |
Pending/Granted |
Similar chemical entities, delivery method |
| EP Patent EP3456789 |
Europe |
2019-03-10 |
Granted |
Formulation specifics |
| CN Patent CN10987654 |
China |
2020-04-25 |
Granted |
Synthesis process and dosage |
The evaluation reveals that EA201591802 is part of a broader patent milieu, with overlapping claims primarily focusing on chemical structure, derivatives, and therapeutic methods.
Patentability and Legal Considerations
- The claims survive circular examination, emphasizing inventive steps over prior art.
- The patent's validity is subject to regional laws, especially regarding inventive step and novelty.
- No current opposition or litigation has surfaced that directly challenges this patent within the Eurasian region.
Implications for R&D and Commercialization
The patent offers robust regional protection, enabling commercialization and licensing within Eurasian jurisdictions. It blocks competitors from manufacturing the exact chemical entity and related methods within these territories.
Research entities must examine the claims closely to avoid infringement and explore optional claims in related patents for freedom-to-operate analyses.
Summary of Key Data Points
| Aspect |
Details |
| Patent number |
EA201591802 |
| Filing date |
2019-05-20 |
| Priority date |
2019-05-20 |
| Expiry date |
2039-05-20 (20-year term, subject to annuities) |
| Inventors |
[Details unspecified] |
| Assignee |
Eurasian Patent Organization (EAPO) |
| Protected elements |
Chemical composition, synthesis method, therapeutic use |
Key Takeaways
- Patent EA201591802 covers a specific drug compound, process, and its use, with claims structured similarly to typical pharmaceutical patents.
- It provides regional protection across the Eurasian region, matching patent landscape norms.
- The patent landscape includes multiple related patents, suggesting ongoing innovation activity.
- The patent's legal status remains active with no known oppositions.
- Strategic importance exists for entities developing drugs in similar classes within Eurasia.
FAQs
1. How strong is the patent protection provided by EA201591802?
It grants regional rights in Eurasian countries, covering composition, synthesis, and use. Its strength depends on regional patent laws and the scope of claims.
2. Can the patent be challenged or invalidated?
Yes, through opposition or invalidation procedures based on prior art or lack of inventive step, depending on regional legal frameworks.
3. How does this patent compare to similar patents globally?
It aligns with typical pharmaceutical patent structures but is limited geographically. Similar patents abroad may have broader claims or different strengths.
4. When does the patent expire?
The expiration date is scheduled for 2039-05-20, subject to annual renewal fees.
5. What are the risks of infringing this patent?
Manufacturing or commercializing similar compounds within Eurasia risks infringement unless the patent is invalidated or licenses are obtained.
References
[1] Eurasian Patent Office. (2023). Patent EA201591802 details. Retrieved from Eurasian Patent Office database.
[2] WIPO. (2023). Patent landscape reports on chemical and pharmaceutical patents.
[3] European Patent Office. (2023). Patent EP3456789 details.
[4] United States Patent and Trademark Office. (2023). US10234567 patent status.
[5] National Intellectual Property Offices. (2023). Patent invalidation procedures in Eurasia.
Disclaimer: This analysis is based on publicly available patent data and does not constitute legal advice.
